Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2013-12-31, filed 2014-02-14, with 12 holding rows worth $267,017,000.

Accession
0001140361-14-007193
Filed
2014-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2013

A holdings report, 12 entries on the cover page, a total value of $267,017,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $267,017,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ARIAD PHARMACEUTICALS INC04033A100COM12,000,000$81,840,000thousands by filing date
QUEST DIAGNOSTICS INC COM74834L100Stock700,000$37,478,000thousands by filing date
IDENIX PHARMACEUTICALS INC45166R204COM5,050,100$30,200,000thousands by filing date
VIVUS INC928551100COM2,573,943$23,371,000thousands by filing date
Merck & Co.,Inc.58933Y105COM400,000$20,020,000thousands by filing date
Mallinckrodt PlcG5785G107SHS280,000$14,633,000thousands by filing date
Bristol-Myers Squibb Company110122108COM250,000$13,288,000thousands by filing date
AbbVie,Inc.00287Y109COM250,000$13,203,000thousands by filing date
Pfizer Inc.717081103COM410,000$12,558,000thousands by filing date
REPROS THERAPEUTICS INC76028H209COM459,508$8,409,000thousands by filing date
BIO REFERENCE LABS INC09057G602COM285,300$7,287,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM2,570,759$4,730,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-14-007193this filing2014-02-14acceptance time not in the bulk data set